Activation of several neurohormonal systems occurs during acute myocardial infarction (AMI) and is associated with short- and long-term outcomes. In the last few years, many circulating factors have received close attention but it is not clear which are the best prognostic indicators of mortality. Renin and natriuretic cardiac peptides appeared to be strong predictors of outcome in patients with AMI, and could represent helpful markers of risk in these patients. Though the role of acute inflammatory markers has been investigated only recently, mounting evidence indicates that C-reactive protein is also associated with an adverse outcome after AMI. Recent research from our laboratory indicates that the albumin excretion rate (AER) is a powerful predictor of the in-hospital and 3-year mortality in patients with AMI and that its prognostic power is stronger than that shown by other humoral markers of risk or by clinical and echocardiographic signs of congestive heart failure. The reason why AER is so closely associated with an adverse prognosis is not completely understood, but the available data support the hypothesis that it reflects both the hemodynamic as well as the inflammatory changes which accompany AMI. The determination of the brain natriuretic peptide and of C-reactive protein appears to be a valuable tool in the risk stratification of subjects with AMI. Even though available evidence is still limited, the evaluation of AER could be useful for the identification of those patients at higher risk for whom additional preventive and therapeutic measures would be advisable.
Download full-text PDF |
Source |
---|
Cardiovasc Diabetol
January 2025
Department of Cardiology, The Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325027, Zhejiang, People's Republic of China.
Background: Hypertension (HTN) is a global public health concern and a major risk factor for cardiovascular disease (CVD) and mortality. Insulin resistance (IR) plays a crucial role in HTN-related metabolic dysfunction, but its assessment remains challenging. The triglyceride-glucose (TyG) index and its derivatives (TyG-BMI, TyG-WC, and TyG-WHtR) have emerged as reliable IR markers.
View Article and Find Full Text PDFCardiovasc Diabetol
January 2025
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Background: The triglyceride‒glucose index (TyG index) is a reliable surrogate for insulin resistance (IR) in individuals with type 2 diabetes mellitus and is associated with cardiovascular disease. Recent studies have reported that H-type hypertension is likewise a predictor of adverse events in patients with coronary heart disease (CHD). However, the relationship between the TyG index and prognosis in patients with H-type hypertension combined with CHD has not yet been reported.
View Article and Find Full Text PDFBMC Ophthalmol
January 2025
Ophthalmology Unit, Queen Margaret Hospital, NHS Fife, Dunfermline, UK.
Background: COVID-19 caused a huge backlog of patients in glaucoma clinics. This study describes redesign of an entire glaucoma service with electronic patient triage to three levels and utilisation of the Scottish optometry infrastructure of upskilled optometrists.
Methods: 2276 patients in glaucoma clinics were identified and triaged to three levels in keeping with Glauc-strat-fast guidance with local amendments.
Insights Imaging
January 2025
Department of Radiology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.
Objective: To assess the utility of clinical and MRI features in distinguishing ovarian clear cell carcinoma (CCC) from adnexal masses with ovarian-adnexal reporting and data system (O-RADS) MRI scores of 4-5.
Methods: This retrospective study included 850 patients with indeterminate adnexal masses on ultrasound. Two radiologists evaluated all preoperative MRIs using the O-RADS MRI risk stratification system.
Nat Rev Urol
January 2025
Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Approximately 20% of paediatric and adolescent/young adult patients with renal tumours are diagnosed with non-Wilms tumour, a broad heterogeneous group of tumours that includes clear-cell sarcoma of the kidney, congenital mesoblastic nephroma, malignant rhabdoid tumour of the kidney, renal-cell carcinoma, renal medullary carcinoma and other rare histologies. The differential diagnosis of these tumours dates back many decades, when these pathologies were identified initially through clinicopathological observation of entities with outcomes that diverged from Wilms tumour, corroborated with immunohistochemistry and molecular cytogenetics and, subsequently, through next-generation sequencing. These advances enabled near-definitive recognition of different tumours and risk stratification of patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!